莫西沙星联合胸腔注入尿激酶治疗结核性胸膜炎的效果  

Efficacy of moxifloxacin combined with intrapleural injection of urokinase on tuberculous pleurisy

作　　者：郭锐[1] Guo Rui(Department of Tuberculosis,Zhengzhou Sixth People’s Hospital,Zhengzhou 450052,China)

机构地区：[1]郑州市第六人民医院结核病科,450052

出　　处：《中国实用医刊》2021年第12期96-98,共3页Chinese Journal of Practical Medicine

摘　　要：目的:探讨莫西沙星联合胸腔注入尿激酶治疗结核性胸膜炎的效果。方法:抽取2015年1月至2019年12月郑州市第六人民医院收治的结核性胸膜炎患者60例,依据治疗方案分为两组,每组30例。对照组给予胸腔注入尿激酶治疗,观察组给予胸腔注入尿激酶联合莫西沙星治疗。回顾性比较两组临床症状缓解时间、治疗前后肺功能指标及胸膜厚度、不良反应。结果:观察组发热停止、胸闷消失、胸腔积液消失时间短于对照组(t=3.516、3.604、4.758,P<0.05)。治疗3个月,两组用力肺活量(FVC)、第1秒用力呼气容积(FEV1)较治疗前升高(P<0.05),且观察组相应值高于对照组(t=2.650、5.049,P<0.05)。治疗3个月,两组胸膜厚度较治疗前减少(F=12.048,P<0.05),且观察组相应值小于对照组(t=13.525,P<0.05)。两组不良反应发生率比较,χ^(2)=0.268,P=0.605。结论:胸腔注入尿激酶联合莫西沙星治疗结核性胸膜炎临床症状缓解时间短,可有效改善胸膜厚度及肺功能,且不增加不良反应。Objective To investigate the efficacy of moxifloxacin combined with intrapleural injection of urokinase on tuberculous pleurisy.Methods A total of 60 patients with tuberculous pleurisy admitted to Zhengzhou Sixth People’s Hospital from January 2015 to December 2019 were selected and divided into two groups according to the treatment plan,with 30 cases in each group.The control group was treated with thoracic injection of urokinase,and the observation group was given intrapleural injection of urokinase combined with moxifloxacin.The clinical symptom relief time,pulmonary function indexes and pleural thickness before and after treatment,and adverse reactions were retrospectively compared between the two groups.Results The time of fever stop,disappearance of chest tightness,and disappearance of pleural effusion in the observation group were shorter than those in the control group(t=3.516,3.604,4.758,P<0.05).After 3 months of treatment,the forced vital capacity(FVC)and forced expiratory volume in the first second(FEV1)in the two groups were higher than those before treatment(P<0.05),and the corresponding values in the observation group were higher than those in the control group(t=2.650,5.049,P<0.05).After 3 months of treatment,the thickness of the pleura in the two groups was reduced tnan that before treatment(F=12.048,P<0.05),and the corresponding value in the observation group was smaller than that in the control group(t=13.525,P<0.05).The incidence of adverse reactions was compared between the two groups,χ^(2)=0.268,P=0.605.Conclusions The pleural injection of urokinase combined with moxifloxacin on tuberculous pleurisy has a short remission time of clinical symptoms,can effectively improve pleural thickness and lung function,and does not increase adverse reactions.

关 键 词：结核 胸膜炎 莫西沙星 肺功能 

分 类 号：R521.7[医药卫生—内科学]